JP2019532953A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532953A5 JP2019532953A5 JP2019517396A JP2019517396A JP2019532953A5 JP 2019532953 A5 JP2019532953 A5 JP 2019532953A5 JP 2019517396 A JP2019517396 A JP 2019517396A JP 2019517396 A JP2019517396 A JP 2019517396A JP 2019532953 A5 JP2019532953 A5 JP 2019532953A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- immune effector
- amino acid
- cancer
- effector cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2016/101213 | 2016-09-30 | ||
| CN2016101213 | 2016-09-30 | ||
| PCT/CN2017/104422 WO2018059549A1 (en) | 2016-09-30 | 2017-09-29 | Immune effector cell therapies with enhanced efficacy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019532953A JP2019532953A (ja) | 2019-11-14 |
| JP2019532953A5 true JP2019532953A5 (https=) | 2021-08-12 |
Family
ID=61763296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517396A Pending JP2019532953A (ja) | 2016-09-30 | 2017-09-29 | 増強された有効性を有する免疫エフェクター細胞治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20190298715A1 (https=) |
| EP (1) | EP3523290A4 (https=) |
| JP (1) | JP2019532953A (https=) |
| CN (1) | CN110582488A (https=) |
| WO (1) | WO2018059549A1 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2958943T3 (da) | 2013-02-20 | 2019-12-09 | Univ Pennsylvania | Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor |
| TW201446794A (zh) | 2013-02-20 | 2014-12-16 | Novartis Ag | 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向 |
| EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| US11028143B2 (en) | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
| SG10201913765YA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| TWI750110B (zh) | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症 |
| ES2791248T3 (es) | 2014-08-19 | 2020-11-03 | Novartis Ag | Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer |
| KR20170068504A (ko) | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
| WO2016115482A1 (en) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| MX2017012939A (es) | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| SG11201708516YA (en) | 2015-04-17 | 2017-11-29 | David Maxwell Barrett | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| AU2016297014B2 (en) | 2015-07-21 | 2021-06-17 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| EP3331913A1 (en) | 2015-08-07 | 2018-06-13 | Novartis AG | Treatment of cancer using chimeric cd3 receptor proteins |
| JP6905163B2 (ja) | 2015-09-03 | 2021-07-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | サイトカイン放出症候群を予測するバイオマーカー |
| EA201891338A1 (ru) | 2015-12-04 | 2018-12-28 | Новартис Аг | Композиции и способы для иммуноонкологии |
| AU2016382512A1 (en) * | 2015-12-30 | 2018-07-12 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| EP3523331A1 (en) | 2016-10-07 | 2019-08-14 | Novartis AG | Chimeric antigen receptors for the treatment of cancer |
| EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| WO2018175636A2 (en) | 2017-03-22 | 2018-09-27 | Novartis Ag | Compositions and methods for immunooncology |
| UY37774A (es) * | 2017-06-19 | 2019-01-31 | Novartis Ag | Compuestos 5-cianoindol sustituidos y usos de los mismos |
| JP7585034B2 (ja) | 2017-10-18 | 2024-11-18 | ノバルティス アーゲー | 選択的タンパク質分解のための組成物及び方法 |
| TW201930591A (zh) | 2018-01-08 | 2019-08-01 | 瑞士商諾華公司 | 用於與嵌合抗原受體療法併用之免疫增強rna |
| CN112533617A (zh) * | 2018-04-25 | 2021-03-19 | 卫理公会医院体系公司 | 癌症新抗原和其在癌症疫苗和基于tcr的癌症免疫疗法中的效用 |
| CA3100724A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof |
| PH12022551291A1 (en) | 2019-11-26 | 2023-11-20 | Novartis Ag | Chimeric antigen receptors binding bcma and cd19 and uses thereof |
| IL292924A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors cd19 and cd22 and their uses |
| CA3170023A1 (en) * | 2020-02-27 | 2021-09-02 | Nanjing Legend Biotech Co., Ltd. | Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof |
| US20230220342A1 (en) * | 2020-04-24 | 2023-07-13 | Georgia State University Research Foundation, Inc. | SIRPa Deficient Macrophages for Treating Cancer |
| US12365871B2 (en) | 2020-04-28 | 2025-07-22 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| EP4168451A2 (en) | 2020-06-22 | 2023-04-26 | NGM Biopharmaceuticals, Inc. | Lair-1-binding agents and methods of use thereof |
| CN116710090A (zh) * | 2020-10-09 | 2023-09-05 | Napa医疗有限公司 | Cd38的杂芳基酰胺抑制剂 |
| CN114426952A (zh) * | 2020-10-29 | 2022-05-03 | 中国科学技术大学 | 用于白血病的car t细胞疗法的t细胞增效剂及获得增效t细胞的方法 |
| WO2022165313A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| TW202307210A (zh) | 2021-06-01 | 2023-02-16 | 瑞士商諾華公司 | Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途 |
| CN113462723B (zh) * | 2021-07-05 | 2023-07-11 | 北京中医药大学 | 表达CAR和shRNA的逆转录病毒载体及其应用 |
| EP4525908A2 (en) * | 2022-05-20 | 2025-03-26 | Imago Biosciences Inc. | Methods for the enhancement of therapeutic effect of car-t cells |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050113564A1 (en) * | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| DE102008052943A1 (de) * | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
| US20140163041A1 (en) * | 2011-02-08 | 2014-06-12 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
| US9289415B2 (en) * | 2011-09-01 | 2016-03-22 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| US10316289B2 (en) * | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
| AU2014248119B2 (en) * | 2013-04-03 | 2019-06-20 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted T-cells derived from pluripotent stem cells |
| CA2916533C (en) * | 2013-06-25 | 2022-12-20 | University Of Canberra | Methods and compositions for modulating cancer stem cells |
| CA2954168C (en) * | 2013-08-02 | 2023-09-19 | The Regents Of The University Of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
| US20150250824A1 (en) * | 2014-03-07 | 2015-09-10 | The Research Foundation For The State University Of New York | Methods and compositions for expansion of stem cells and other cells |
| JP2017508798A (ja) * | 2014-03-07 | 2017-03-30 | ザ ジョンズ ホプキンス ユニバーシティ | ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤 |
| SI3137169T1 (sl) * | 2014-05-01 | 2022-04-29 | Celgene Quanticel Research, Inc. | Inhibitorji lizin specifične demetilaze-1 |
| US10233165B2 (en) * | 2014-05-30 | 2019-03-19 | Istituto Europeo Di Oncologia S.R.L. | Cyclopropylamine compounds as histone demethylase inhibitors |
| TWI750110B (zh) * | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症 |
| CA2958704A1 (en) * | 2014-08-25 | 2016-03-03 | University Of Canberra | Compositions for modulating cancer stem cells and uses therefor |
| AU2016382512A1 (en) * | 2015-12-30 | 2018-07-12 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
| CN110267945A (zh) * | 2016-03-01 | 2019-09-20 | 诺华股份有限公司 | 氰基取代的吲哚化合物及其作为lsd1抑制剂的用途 |
-
2017
- 2017-09-29 WO PCT/CN2017/104422 patent/WO2018059549A1/en not_active Ceased
- 2017-09-29 JP JP2019517396A patent/JP2019532953A/ja active Pending
- 2017-09-29 EP EP17854999.4A patent/EP3523290A4/en not_active Withdrawn
- 2017-09-29 US US16/338,085 patent/US20190298715A1/en not_active Abandoned
- 2017-09-29 CN CN201780073475.5A patent/CN110582488A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532953A5 (https=) | ||
| JP2019500394A5 (https=) | ||
| RU2018127657A (ru) | Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью | |
| JP2018527008A5 (https=) | ||
| JP2020513828A5 (https=) | ||
| RU2019133286A (ru) | Биомаркеры и средства терапии на основе т-клеток с car с повышенной эффективностью | |
| US11564945B2 (en) | Chimeric antigen receptor and use thereof | |
| JP2017513818A5 (https=) | ||
| JP2021534783A5 (https=) | ||
| JPWO2020047452A5 (https=) | ||
| JP2020506700A5 (https=) | ||
| JP2019525956A5 (https=) | ||
| JP2020500530A5 (https=) | ||
| WO2018059549A1 (en) | Immune effector cell therapies with enhanced efficacy | |
| JP2024045111A (ja) | ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法 | |
| JPWO2016028896A5 (https=) | ||
| CN116082518A (zh) | 一种结合bcma的嵌合抗原受体（car）及其应用 | |
| JP2017522879A5 (https=) | ||
| JP2016514462A5 (https=) | ||
| JP2017524367A5 (https=) | ||
| JP2017527271A5 (https=) | ||
| US12178786B2 (en) | Combination of cellular immunotherapy | |
| JP2022524906A (ja) | 細胞免疫療法の組み合わせ | |
| JP2022517301A (ja) | 腫瘍併用免疫療法 | |
| CN112040957A (zh) | 靶向表达cd99的癌症的组合物和方法 |